Sourcing · Regulatory · continued

Revisiting: Why a compound being unapproved is not the same as being illegal to possess posts 31–60

Sourcing › Regulatory FDA EMA compounding research use only Closed

This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.

k.farrugiaTL3Regular22 Jun 2025 · edited#31

dr_bhattacharya, post #7: Picking up post #6: that is the part I would want checked first. Preclinical versus clinical: compounds with strong preclinical data can fail in clinical trials. Compounds with no human data are being used on theoretical grounds. The regulatory position reflects this asymmetry. Posting it because the silence on this was starting to look… Go to post

I think the compound being unapproved question is answerable and has not been answered, which is a more optimistic position than most of this thread.

23 likes in reply to #7 13mo

m.yildizTL223 Jun 2025#32

k.farrugia, post #31: I think the compound being unapproved question is answerable and has not been answered, which is a more optimistic position than most of this thread. Go to post

Understood, and I withdraw the assumption I opened with.

10 likes in reply to #31 13mo

lyophil_marginTL3Regular24 Jun 2025#33

Post #29 describes the usual case. This is about the unusual one.

If you can confirm or contradict a position for your own region, please date the answer. An undated regional claim is the least useful thing in this category.

That is what the documentation says. What happens in practice is usually close.

3 likes 13mo

e.kuipersTL225 Jun 2025#34

Adding the measurement that post #33 says would settle it.

Preclinical versus clinical: compounds with strong preclinical data can fail in clinical trials. Compounds with no human data are being used on theoretical grounds. The regulatory position reflects this asymmetry.

0 likes 13mo

e.mikkelsenTL2Member27 Jun 2025#35

A compound in a compounding pathway in one country and unavailable in another is a common situation and produces most of the confusion here.

31 likes 13mo

z.nakamuraTL228 Jun 2025#36

k.farrugia, post #31: I think the compound being unapproved question is answerable and has not been answered, which is a more optimistic position than most of this thread. Go to post

Distinguishing three things in the compound being unapproved discussion that keep getting used interchangeably: the observation, the proposed mechanism, and the recommendation that gets attached to both.

16 likes in reply to #31 13mo

r.torrenceTL2Member29 Jun 2025#37

Compound being unapproved would be much easier to settle if anyone reported the denominator. Almost nobody reports the denominator.

6 likes 13mo

r.oyelaranTL230 Jun 2025#38

The arithmetic in post #37 is right; the assumption feeding it is the part to check.

An indication approved for one age range does not extend to another, and paediatric extensions are separate decisions with separate evidence.

The confident version of this sentence would be wrong, so here is the hedged one.

1 like 13mo

MSaarinenTL3Regular2 Jul 2025#39

r.oyelaran, post #38: The arithmetic in post #37 is right; the assumption feeding it is the part to check. An indication approved for one age range does not extend to another, and paediatric extensions are separate decisions with separate evidence. The confident version of this sentence would be wrong, so here is the hedged one. Go to post

I had read the opposite somewhere and cannot now find where, which tells me something.

11 likes in reply to #38 13mo

e.krastevTL23 Jul 2025#40

Import restrictions vary by compound and by jurisdiction: what is a controlled substance in one place is legal to purchase in another. What you can import for personal use depends on your country's rules, not on where it is sold.

The conclusion is tentative; the arithmetic underneath it is not.

3 likes 13mo

k.batistaTL24 Jul 2025#41

Compound being unapproved: I would want to see the raw numbers rather than the summary before agreeing. Summaries lose exactly the information that would settle this.

30 likes 13mo

methods_marginTL3Regular5 Jul 2025#42

I had written a reply contradicting post #40 and deleted it. Here is what survived.

The reason compound being unapproved is hard to answer is that the obvious measurement and the relevant quantity are not the same thing, and substituting one for the other is silent.

0 likes 13mo

n.boatengTL26 Jul 2025#43

Picking up post #42: that is the part I would want checked first.

Labelling and intended use: a compound sold as "research-use-only" does not change its pharmacology if ingested. It changes the legal status of the sale. The labelling tells you the intended use, not the actual use people make of it.

5 likes 13mo

crossover_reviewTL3Regular7 Jul 2025#44

r.torrence, post #37: Compound being unapproved would be much easier to settle if anyone reported the denominator. Almost nobody reports the denominator. Go to post

Practical experience of compound being unapproved, offered as one case with the conditions stated, not as a general finding. Conditions first, because they are what make it interpretable.

15 likes in reply to #37 13mo

n.kaufmannTL29 Jul 2025 · edited#45

g.tanaka, post #9: Narrowing post #6, because the general version has more than one answer. Import restrictions vary by compound and by jurisdiction: what is a controlled substance in one place is legal to purchase in another. What you can import for personal use depends on your country's rules, not on where it is sold. Adding a source would improve this… Go to post

I would be cautious about generalising from the compound being unapproved example above. It is a good example. It is one example.

22 likes in reply to #9 13mo

vial_slopeTL3Regular10 Jul 2025#46

Coming back to post #44, because the follow-up matters more than the original answer.

Generic or biosimilar entry depends on patent and exclusivity positions that are jurisdiction-specific and are frequently misreported.

0 likes 13mo

m.guerreroTL211 Jul 2025#47

Collapsed as off-topic by two members at trust level 3 or above

This follows post #46 rather than contradicting it.

A regulator's public assessment report is usually the single best free source on a compound's evidence base, and it is almost never cited here.

stopper_traceTL2Member12 Jul 2025#48

Regulatory positions change: a compound's status today might differ from its status a year from now. Citing a regulatory position is worth doing only with a date attached.

Old habit: I write down the expected answer before I calculate it.

10 likes 13mo

i.beaulieuTL213 Jul 2025#49

methods_margin, post #42: I had written a reply contradicting post #40 and deleted it. Here is what survived. The reason compound being unapproved is hard to answer is that the obvious measurement and the relevant quantity are not the same thing, and substituting one for the other is silent. Go to post

Post #46 answers the question as asked. The question underneath it is different.

16 likes in reply to #42 13mo

IMainwaringTL3Regular14 Jul 2025#50

I read post #48 twice before replying, because I had assumed the opposite.

Nothing in this subcategory is legal advice, and the members who work in regulated environments are the most careful to say so.

That is the version I would defend. It is not the version I started with.

31 likes 12mo

r.chukwuTL215 Jul 2025 · edited#51

m.broberg, post #14: Whatever the answer on compound being unapproved turns out to be, the method for getting there is the same: state the assumption, do the arithmetic in public, invite the correction. Go to post

I read post #48 twice before replying, because I had assumed the opposite.

Approval versus licensing: a compound can be approved for a specific indication in one country and not approved at all in another. Tracking jurisdictional approval is tedious but necessary.

20 likes in reply to #14 12mo

TavaresTL1Member17 Jul 2025#52

r.aldana_pharmd, post #3: Small methodological point on compound being unapproved: repeating a measurement is cheap and resolves most of what is being argued about here at no cost to anyone. Go to post

Genuine question rather than a rhetorical one: has anyone here actually observed compound being unapproved, as opposed to read about it? The thread is long and I cannot tell.

9 likes in reply to #3 12mo

r.mwangiTL218 Jul 2025#53

Nothing in this subcategory is legal advice, and the members who work in regulated environments are the most careful to say so.

A modest claim, modestly supported.

0 likes 12mo

BramleyTL2Member19 Jul 2025#54

Written from notes rather than memory, which is why the numbers are specific.

0 likes 12mo

m.adebayoTL220 Jul 2025#55

Everything in post #51 holds. The case it does not cover is the one I have.

I would call the community position on compound being unapproved likely rather than established, and I would be comfortable defending that hedge.

28 likes in reply to #9 12mo

bench_peakTL3Regular21 Jul 2025#56

Narrowing post #55, because the general version has more than one answer.

Compounding and pharmacy rules: some jurisdictions allow a pharmacy to compound a drug that is not on the market under specific conditions. The conditions are strict and vary by jurisdiction. Generalising from one country's rules to another's is unreliable.

14 likes 12mo

p.boatengTL222 Jul 2025#57

The failure mode on compound being unapproved is boring rather than dramatic. It is almost always the step everyone assumes was done correctly because it is too simple to get wrong.

2 likes 12mo

l.chevalierTL3Regular23 Jul 2025#58

Agreed on all of that, and I have nothing to add to it.

0 likes 12mo

d.barrosTL224 Jul 2025#59

m.guerrero, post #47: This follows post #46 rather than contradicting it. A regulator's public assessment report is usually the single best free source on a compound's evidence base, and it is almost never cited here. Go to post

No notes. Posting so the count is not one.

9 likes in reply to #47 12mo

m.ivaturiTL225 Jul 2025#60

The arithmetic in post #57 is right; the assumption feeding it is the part to check.

What I can speak to on compound being unapproved is narrow, so I will keep it narrow rather than generalising from it. Beyond that boundary I do not know.

2 likes 12mo